Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac involvement in scleroderma

A Deswal1, W P Follansbee

  • 1University of Pittsburgh School of Medicine, Pennsylvania, USA.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident.

Alimentary pharmacology & therapeutics·2007
Same author

Experimental options in the treatment of heart failure: the role of cytokine antagonism.

Heart failure monitor·2003
Same author

Trials within trials: confirmatory subgroup analyses in controlled clinical experiments.

Controlled clinical trials·2001
Same author

Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial.

Chest·2001
Same author

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

Circulation·2001
Same author

The role of anti-cytokine therapy in the failing heart.

Heart failure reviews·2001
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Cardiac involvement in systemic sclerosis, including myocardial and conduction abnormalities, is common, especially in diffuse disease, and indicates a poor prognosis. Current treatments are symptomatic, with further research needed on vasodilation and immunosuppression.

Area of Science:

  • Cardiology
  • Rheumatology
  • Systemic Sclerosis Research

Background:

  • Systemic sclerosis frequently involves the heart, manifesting in various forms like myocardial, pericardial, and conduction system diseases.
  • Cardiac involvement in systemic sclerosis is a significant indicator of a poor prognosis.
  • Abnormalities are more prevalent in diffuse scleroderma, with vascular involvement's role remaining uncertain.

Purpose of the Study:

  • To summarize the clinical manifestations and prognostic implications of cardiac involvement in systemic sclerosis.
  • To highlight the frequency of asymptomatic cardiac abnormalities.
  • To discuss current therapeutic strategies and future research directions for cardiac scleroderma.

Main Methods:

  • Review of clinical findings and prognostic factors in systemic sclerosis.

Related Experiment Videos

  • Analysis of the prevalence of cardiac abnormalities based on disease subtype (diffuse scleroderma).
  • Evaluation of current treatment approaches and identification of areas for further investigation.

    • Main Results:

    • Cardiac involvement in systemic sclerosis presents as myocardial, pericardial, conduction system disease, or arrhythmias.
    • Clinical cardiac involvement is a poor prognostic factor.
    • Asymptomatic cardiac abnormalities are frequent, particularly in diffuse scleroderma.

    Conclusions:

    • Cardiac manifestations are a critical aspect of systemic sclerosis, impacting prognosis significantly.
    • Current treatments for cardiac scleroderma are primarily symptomatic and empirical.
    • Further research is essential to explore the potential of vasodilation and immunosuppression in managing cardiac scleroderma.